Approval to start IMPACT
16. September 2020
IMPACT, a study in collaboration with Imcyse SA, is now approved in both Belgium and the UK. 10 sites over 2 countries will be active soon. The aim of the trial is to preserve the betacell function in young adult and adolescent type one diabetes patients with the drug Imotope™ IMCY-0098. Detailed information following soon on the INNODIA website.
